When the initial letter score was less than @ ( approximately @/@ or worse ) , the mean improvement was @ with aflibercept , @ with bevacizumab , and @ with ranibizumab ( P < @ for aflibercept vs. bevacizumab , P = @ for aflibercept vs. ranibizumab , and P = @ for ranibizumab vs. bevacizumab ) .